帕利普韦 T22394

Product Introduction
Bioactivity


英文名: Paritaprevir

描述: Paritaprevir (ABT450) 是一种非结构蛋白 3/4A 蛋白酶抑制剂，对 HCV 1a 和 HCV 1b 的 EC50 值分别为 1 和 0.21 nM。它也是SARS-CoV 3CLpro 的抑制剂，IC50为 1.31 μM。

体内活性: Paritaprevir/ritonavir/ombitasvir with dasabuvir (PrOD) is a novel combination of a nonstructural (NS) 3/4A protein inhibitor boosted by ritonavir, an NS5A protein inhibitor, and an NS5B nonnucleoside polymerase inhibitor. The combination of paritaprevir, ritonavir, ombitasvir (an NS5A protein inhibitor), and dasabuvir (an NS5B non-nucleoside polymerase inhibitor) with or without RBV has been approved to treat HCV genotype 1 infections1[1].

存储条件: Powder: -20°C for 3 years | In solvent: -80°C for 1 year

溶解度: DMSO : 80 mg/mL (104.46 mM)


关键字: orally active | HCV Protease | Ritonavir | SARS-CoV | Hepatitis C virus | HCV | SARS coronavirus | Paritaprevir | ABT 450 | NS3/4A | Inhibitor | CYP450 | SARS-CoV 3CLPpro | inhibit

相关产品: VCH-916 | Sofosbuvir impurity A | Coblopasvir dihydrochloride | R-1479 | Inarigivir soproxil | Daclatasvir dihydrochloride | Maribavir | Merimepodib | Sofosbuvir impurity M | Platycodin D3

相关库: FDA-Approved Drug Library | Drug Repurposing Compound Library | Approved Drug Library | Clinical Compound Library | Inhibitor Library | EMA Approved Drug Library | Protease Inhibitor Library | Anti-Viral Compound Library | Bioactive Compound Library | Anti-Infection Compound Library

帕利普韦 T22394信息由TargetMol中国为您提供，如您想了解更多关于帕利普韦 T22394报价、型号、参数等信息，欢迎来电或留言咨询。

注：该产品未在中华人民共和国食品药品监督管理部门申请医疗器械注册和备案，不可用于临床诊断或治疗等相关用途